ELEV vs. RAIN, SCYX, BOLT, SBBP, DMAC, GALT, ABOS, PRQR, RANI, and CHRS
Should you be buying Elevation Oncology stock or one of its competitors? The main competitors of Elevation Oncology include Rain Oncology (RAIN), SCYNEXIS (SCYX), Bolt Biotherapeutics (BOLT), Strongbridge Biopharma (SBBP), DiaMedica Therapeutics (DMAC), Galectin Therapeutics (GALT), Acumen Pharmaceuticals (ABOS), ProQR Therapeutics (PRQR), Rani Therapeutics (RANI), and Coherus BioSciences (CHRS). These companies are all part of the "medical" sector.
Rain Oncology (NASDAQ:RAIN) and Elevation Oncology (NASDAQ:ELEV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.
Elevation Oncology has a consensus price target of $7.80, suggesting a potential upside of 1,148.00%. Given Elevation Oncology's higher possible upside, analysts plainly believe Elevation Oncology is more favorable than Rain Oncology.
Elevation Oncology is trading at a lower price-to-earnings ratio than Rain Oncology, indicating that it is currently the more affordable of the two stocks.
Rain Oncology has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.
Elevation Oncology's return on equity of -57.97% beat Rain Oncology's return on equity.
Elevation Oncology received 4 more outperform votes than Rain Oncology when rated by MarketBeat users. Likewise, 73.17% of users gave Elevation Oncology an outperform vote while only 52.00% of users gave Rain Oncology an outperform vote.
In the previous week, Rain Oncology had 5 more articles in the media than Elevation Oncology. MarketBeat recorded 6 mentions for Rain Oncology and 1 mentions for Elevation Oncology. Elevation Oncology's average media sentiment score of 0.00 beat Rain Oncology's score of -0.29 indicating that Elevation Oncology is being referred to more favorably in the news media.
65.8% of Rain Oncology shares are held by institutional investors. Comparatively, 83.7% of Elevation Oncology shares are held by institutional investors. 17.4% of Rain Oncology shares are held by company insiders. Comparatively, 8.1% of Elevation Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Elevation Oncology beats Rain Oncology on 11 of the 14 factors compared between the two stocks.
Get Elevation Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELEV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELEV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elevation Oncology Competitors List
Related Companies and Tools
